Profiling placental and fetal DNA methylation in human neural tube defects by E. Magda Price et al.
Price et al. Epigenetics & Chromatin  (2016) 9:6 
DOI 10.1186/s13072-016-0054-8
RESEARCH
Profiling placental and fetal DNA 
methylation in human neural tube defects
E. Magda Price1,2,3, Maria S. Peñaherrera1,2, Elodie Portales‑Casamar1, Paul Pavlidis4,5, Margot I. Van Allen2, 
Deborah E. McFadden2,6 and Wendy P. Robinson1,2*
Abstract 
Background: The incidence of neural tube defects (NTDs) declined by about 40 % in Canada with the introduction 
of a national folic acid (FA) fortification program. Despite the fact that few Canadians currently exhibit folate defi‑
ciency, NTDs are still the second most common congenital abnormality. FA fortification may have aided in reducing 
the incidence of NTDs by overcoming abnormal one carbon metabolism cycling, the process which provides one car‑
bon units for methylation of DNA. We considered that NTDs persisting in a folate‑replete population may also occur 
in the context of FA‑independent compromised one carbon metabolism, and that this might manifest as abnormal 
DNA methylation (DNAm). Second trimester human placental chorionic villi, kidney, spinal cord, brain, and muscle 
were collected from 19 control, 22 spina bifida, and 15 anencephalic fetuses in British Columbia, Canada. DNA was 
extracted, assessed for methylenetetrahydrofolate reductase (MTHFR) genotype and for genome‑wide DNAm using 
repetitive elements, in addition to the Illumina Infinium HumanMethylation450 (450k) array.
Results: No difference in repetitive element DNAm was noted between NTD status groups. Using a false discovery 
rate <0.05 and average group difference in DNAm ≥0.05, differentially methylated array sites were identified only in 
(1) the comparison of anencephaly to controls in chorionic villi (n = 4 sites) and (2) the comparison of spina bifida to 
controls in kidney (n = 3342 sites).
Conclusions: We suggest that the distinctive DNAm of spina bifida kidneys may be consequent to the neural tube 
defect or reflective of a common etiology for abnormal neural tube and renal development. Though there were some 
small shifts in DNAm in the other tested tissues, our data do not support the long‑standing hypothesis of general‑
ized altered genome‑wide DNAm in NTDs. This finding may be related to the fact that most Canadians are not folate 
deficient, but it importantly opens the field to the investigation of other epigenetic and non‑epigenetic mechanisms 
in the etiology of NTDs.
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Background
Neural tube defects (NTDs) are a spectrum of severe and 
often lethal congenital abnormalities that arise in the first 
month of pregnancy from a failure of the flat neural plate 
to elevate, fold, and close in the developing embryo [1, 2]. 
Folic acid (FA, synthetic folate) fortification and supple-
mentation programs in more than 80 countries around 
the world [3] were initiated in response to mounting 
evidence that the incidence of NTDs could be lowered 
by increasing maternal pre- and perinatal FA intake [4]. 
Despite a 40  % decline in the incidence of NTDs [5], a 
2007 Canadian post FA fortification survey reported that 
the most common NTDs—spina bifida (SB, caudal fail-
ure of neural tube closure) and anencephaly (AN, cranial 
failure of neural tube closure)—were still prevalent at 
respective rates of 0.41 and 0.36 per 1000 live-and still-
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The mechanism through which FA helps to prevent 
NTDs is unclear. Folate is a substrate for the activation 
of methyl groups in one-carbon metabolism (OCM), 
a biochemical pathway comprising two intersecting 
cycles: the DNA cycle (producing nucleotide precursors) 
and the methylation cycle (producing methyl donors) 
[7]. A hypothesis of altered capacity for DNA meth-
ylation (DNAm) has been proposed as the mechanism 
underlying FA prevention of NTDs [8]. The basis of this 
hypothesis was the observation of increased incidence 
of NTDs in association with maternal and fetal SNPs in 
methylenetetrahydrofolate reductase (MTHFR) [9], the 
enzyme at the intersection of the DNA and methylation 
cycles. These MTHFR variants result in reduced enzy-
matic activity [10, 11] which is expected to shift OCM 
toward the DNA cycle, restricting methylation capacity 
and leading to abnormal patterns of DNAm [8, 12]. Stud-
ies in mice demonstrate that the de novo DNA methyl-
transferase, Dnmt3b, is expressed in the elevating neural 
folds during neural tube formation, and that Dnmt3b 
null mutants develop NTDs [13]. Research from coun-
tries without FA fortification also lends support to the 
methylation hypothesis. A slight reduction in genome-
wide DNAm was noted in NTD cases in China [14–16], 
in addition to changes in NTD DNAm at specific genes 
relevant to fetal development in China, Belgium, and the 
Netherlands: imprinted [17], planar-cell polarity [18, 19], 
HOX [20], and folate receptor genes [21]. Some of the 
findings are, however, undermined by small magnitude of 
change in DNAm, a lack of statistical correction for mul-
tiple comparisons, and use of peripheral tissues. Despite 
research and policy changes, NTDs remain the second 
most common congenital abnormality in many parts 
of the world [22], and the etiology of persisting cases is 
unknown.
In this study, we profiled DNAm of NTDs in British 
Columbia  (B.C.), Canada, a population in which folate 
deficiency is rarely observed [23]. However, vitamin 
B12 insufficiency (a cofactor in OCM) has been noted 
in Canadian women of childbearing age [24] and low 
maternal serum B12 levels have been associated with an 
increased risk for NTDs [25, 26]. We therefore consid-
ered that in folate replete populations, the same pathways 
through which FA fortification has contributed to reduc-
ing the incidence of NTDs may be dysregulated, but by 
a different mechanism, and also manifest as abnormal 
NTD DNAm. A unique set of multiple tissues was col-
lected from second trimester (14–26  weeks) human 
fetuses with spina bifida (SB, n = 22) or anencephaly (AN, 
n = 15) in addition to controls (CON, n = 19), to explore 
DNAm using repetitive elements and the Illumina Infin-
ium HumanMethylation450 BeadChip (450k array) plat-
form. The 450k array assesses DNAm at >450,000 CpG 
sites throughout the genome, with coverage of 99  % of 
RefSeq genes and 96 % of CpG islands, allowing the user 
to obtain a highly accurate snapshot of DNAm at ~1.7 % 
of all CpGs [27]. We reasoned that observed changes in 
DNAm in NTDs might be restricted to a single disease-
affected tissue (spinal cord or brain) or support tissue 
(chorionic villi). Alternatively, abnormal DNAm may be 
present in multiple tissues (including those peripheral 
to the defect, like kidney or muscle), as an imprint of an 
insult early in embryo development. Due to the essential 
role that products of OCM play in cell proliferation, dif-
ferentiation, and migration [12, 28], NTDs might be asso-
ciated with (1) changes in DNAm at a specific subset of 
loci (which may contribute to the development of NTDs 
or be a direct consequence of a causative pathway) or (2) 
widespread and/or non-specific changes in DNAm.
Methods
Ethics approval
Ethics approval for this study was obtained from the 
University of British Columbia Children’s and Women’s 
Research Ethics Board (certificate number: H10—1028). 
Written consent was obtained for cases ascertained prior 
to pregnancy termination (n  =  8). For cases obtained 
retrospectively from pathological autopsy specimens 
(n = 48), biospecimens were de-identified and unlinked 
to clinical data. For all cases, only non-identifiable infor-
mation is presented in this publication.
Sample collection
Tissue samples from second trimester (14–26 weeks ges-
tational age) stillbirths, elective terminations, and spon-
taneous abortions were collected by the Embryo-Fetal 
Pathology laboratory at the B.C. Women’s Hospital and 
Health Centre, Vancouver, Canada. Exclusion criteria for 
control cases included chromosomal abnormality, con-
genital or brain abnormality, or grossly abnormal pla-
centa. The use of second trimester fetal tissues required 
the inclusion of samples from complicated pregnancies. 
However, multiple pathologies were included to obtain 
a heterogeneous reference control group and minimize 
the likelihood of significant findings in association with 
any given pathology. For controls with known mode of 
fetal demise  (n = 16), the distribution is as follows: five 
cases with preterm premature rupture of membranes 
(PPROMs), three cases of chorioamnionitis, two cases 
of oligohydramnios, and one case with each of: cervical 
incompetence, copper intrauterine device (IUD), severe 
IUGR, intrauterine fetal demise, spontaneous abortion, 
and hypoplastic left heart syndrome. In the NTD groups, 
chromosomally normal cases with isolated spina bifida or 
anencephaly were included, and the mode of termination 
was heterogeneous within each NTD group. Whenever 
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possible, a sample of fetal kidney (cortex and medulla), 
brain (cortex), spinal cord (thoracic region or superior 
to the lesion in SB), muscle (psoas), and placental chori-
onic villi were obtained for each of 22 SB-affected fetuses, 
15 AN-affected fetuses, and 19 CON fetuses (Additional 
file 1: Table S1); a total of 187 samples were run on the 
450k array. Placental chorionic villi was obtained from an 
additional 9 SB, 11 AN, and 9 CON for follow-up pyrose-
quencing analyses (Additional file 1: Table S2). DNA was 
extracted from samples by standard salting out method. 
Our previous studies have shown that DNAm varies 
across the placenta [29, 30]; thus, to obtain a more accu-
rate assessment, two independent sites (one proximal 
to the cord insertion and one midway between the cord 
and placental edge) were taken from the fetal side of each 
placenta and extracted DNA was combined for DNAm 
analyses.
Case characteristics
Clinical case characteristics are presented in Table 1. SB 
and AN were compared as separate NTD status groups 
throughout the study, as they may have distinct etiologies 
[31]. Although the range of gestational ages overlapped, 
CON cases were younger than SB cases at delivery 
(median 19.0 vs. 21.8  weeks, p =  0.0004), and included 
fewer males (37 vs. 73 %, p = 0.03). These clinical char-
acteristics did not differ between the AN group and CON 
(Table 1). A detailed list of sample information, including 
clinical characteristics and technical variables relating to 
running of the 450k array, is available in Additional file 1: 
Table S1.
MTHFR genotyping
MTHFR genotype was assessed at two loci in each 
case: at nucleotide 677C>T (rs1801133) and 1298A>C 
(rs1801131). In all individuals but one, chorionic villi was 
available for genotyping; in the exceptional case, kidney 
was used in lieu of chorionic villi. Primer sequences and 
reaction conditions can be found in Additional file  1: 
Table S3. 5 µL of PCR product was sequenced on a Pyro-
mark Q96 MD Pyrosequencer (Qiagen) using standard 
protocols.
Illumina Infinium HumanMethylation450 BeadChip (450k) 
quality control and pre‑processing
Genomic DNA was purified and bisulfite converted as 
in Price et  al., 2013. Samples were randomized across 3 
MSA-4 plates for processing following the Illumina Infin-
ium HumanMethylation450 BeadChip protocol [27]. Raw 
intensity was read into Illumina GenomeStudio Software 
2011.1 and background normalization was applied.
On each array, Illumina included 835 control probes 
to assess, for example, array staining, extension, and 
bisulfite conversion. An initial quality control (QC) 
check following Illumina protocol was performed using 
the control probes, with no samples, chips, or batches 
identified as outliers. Signal intensity exported from 
GenomeStudio was read into R statistical software [32] 
Table 1 Clinical characteristics of cases








(CON vs SB; CON vs AN)
Fetal GA (weeks); median (range) 19.0 (14.5–23.9) 21.8 (19.4–23.7) 20.0 (16.7–23.3) 0.0004, ns
Maternal age (years); median (range) 30.0 (21.0–41.0) 30.0 (20.1–40.5) 30.4 (22.8–37.3) ns, ns
Fetal sex; n male (% male) 7 (37) 16 (73) 5 (33) 0.03, ns
Fetal MTHFR677 genotype; n (%) ns, ns
 CC 12 (63) 11 (50) 6 (40)
 CT 7 (37) 7 (32) 8 (53)
 TT 0 (0) 4 (18) 1 (7)
Fetal MTHFR1298 genotype; n (%) ns, ns 
 AA 8 (42) 14 (64) 6 (40)
 AC 9 (47) 6 (27) 8 (53)
 CC 2 (11) 2 (9) 1 (7)
Available tissues; n (%)
 Chorionic villi 16 (84) 22 (100) 14 (93)
 Kidney 16 (84) 20 (91) 8 (53)
 Spinal cord 9 (47) 17 (77) 6 (40)
 Brain 11 (58) 9 (41) –
 Muscle 13 (68) 10 (45) 8 (53)
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using lumi [33] to convert signal intensities to M values. 
Extensive QC was conducted to check sample identity 
using (1) clustering of samples originating from the same 
individual with 65 450k SNP probes; (2) clustering of 
samples by sex with 450k chr X and Y probes; and (3) 
clustering of samples with their respective tissue using 
all autosomal probes. Finding no mislabeled samples, 
sample quality was next assessed using (1) the number 
of probes with a detection p value >0.01; (2) the num-
ber of probes with <3 bead replicates; and (3) the average 
sample intensity. Four samples were identified as outliers 
based on sample quality checks and removed from fur-
ther analyses.
Probe filtering was next conducted to eliminate sys-
temically poor quality probes (detection p value >0.01 
in >20  % of samples or <3 bead replicates in >20  % of 
samples; n  =  587), probes targeting the sex chromo-
somes (n = 11,345), polymorphic probes (n = 20,573), 
and probes that potentially cross-hybridize to the sex 
chromosomes (n = 10,672), as annotated in [34]. Color 
correction [33] to correct for red-green color chan-
nel bias and SWAN normalization [35] to correct for 
type I–type II probe bias were applied. M values were 
replaced with missing values in the remaining probe-
sample pairs with detection p values >0.01 or <3 bead 
replicates.
Principal component analysis was used to detect batch 
effects within each tissue. MSA-4 plate, Sentrix_row (i.e., 
chip row), and Sentrix_ID (i.e., chip ID) were found to be 
associated with variability in the dataset and were sub-
sequently corrected for using ComBat [36]. Prior to cor-
rection, an additional 244 probes were removed from all 
samples since there were less than two values for one of 
the three batch variables, resulting in 183 samples and 
442,156 probes. Successive rounds of batch correction 
were applied starting by correcting for MSA-4 plate, fol-
lowed by Sentrix_row then Sentrix_ID.
The correlation of two replicate pairs (one chori-
onic villi, one kidney sample) was used as a QC met-
ric throughout pre-processing of the dataset; starting 
in the raw data with r_chorionic villi  =  0.9953467 
and r_kidney  =  0.989889 and ending with r_chorionic 
villi = 0.9959680 and r_kidney = 0.9947478 in the batch-
corrected data. With one sample of each replicate pair 
removed and removal of the 65 SNP probes, the final 
450k array dataset included 179 samples and 442,091 
“clean probes”: 52 chorionic villus samples, 44 kidney 
samples, 32 spinal cord samples, 20 brain samples, and 31 
muscle samples (Additional file 1: Table S1).
Probe to gene annotation
For gene-based analyses, a single gene name was anno-
tated to each 450k CpG site in the following manner: (1) 
sites with no Illumina-annotated UCSC_refgene_name 
were annotated as NA; (2) sites with one or more gene 
name entries in the Illumina-annotated UCSC_ref-
gene_name and where all gene names were identical 
were annotated to the given gene; (3) sites with multiple 
differing gene name entries in the Illumina-annotated 
UCSC_refgene_name, were annotated to the closest tran-
scription start site (TSS) based on GPL16304 annota-
tion in the Closest_TSS_gene_name column [34]. Probes 
that fell into category (1) were distant from TSSs. These 
were not annotated to a gene as the regulation of DNAm 
at these CpG sites may not be determined by the closest 
TSS.
Differential methylation analyses
Differential methylation (DM) was assessed within a 
tissue by applying a linear model to M values on a per 
CpG-level using the R package limma [37]. In modeling 
DNAm, NTD status (CON, SB, AN) was used as the main 
effect and fetal sex and gestational age were included as 
additive covariates. DM results were extracted for the 
comparison of SB to CON and AN to CON. Resulting 
p values were adjusted using the Benjamini and Hoch-
berg [38] false discovery rate (FDR) method in the limma 
topTable function.
M values corrected for fetal sex and gestational age 
were transformed to ß values using the m2beta func-
tion in lumi [33]. For every CpG site, average DNAm 
was calculated within each tissue by taking the mean β 
value for each of CON, SB, and AN, with missing data 
points stripped prior to calculation. Group differences in 
DNAm (deltaβ) were then calculated by subtracting the 
CON average ß from each of the SB and AN average ß 
per CpG site. Significant DM CpG sites were considered 
as those with an FDR <0.05 and deltaβ ≥0.05.
Biologically relevant candidate CpG site analysis
DM analysis was conducted as outlined above, using only 
a subset of biologically relevant candidate CpG sites. Bio-
logically relevant candidate CpG sites were chosen as 
those mapping to the following genes: (1) where a muta-
tion of the homologous gene in mice has been shown to 
result in NTDs [39], (2) thought to be associated with 
human cases of NTDs [40], or (3) annotated to the GO 
term “one carbon metabolism process” (GO:0006730). 
340 genes met one or more of these criteria, and the 
8393 probes associated with these genes were used in the 
biologically relevant CpG site analysis (Additional file 1: 
Table S4).
Genome‑wide analyses–450k array
Unsupervised hierarchical clustering was performed 
using all clean, gestational age, and sex corrected data 
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(n  =  442,091 CpG sites, n  =  179 samples). The dis-
similarity structure of the data was calculated using the 
Euclidean method with average agglomeration. An array 
average DNAm was calculated for each sample by aver-
aging DNAm at all clean CpG sites corrected for gesta-
tional age and sex (n = 442,091) with missing data points 
stripped prior to calculation. The percentage of outlier 
probes per sample was calculated in two steps. First, 
the number of outlier probes per sample was calculated 
within each tissue. A probe was considered an outlier if it 
was greater than three median absolute deviations from 
the probe median for all samples in the given tissue [41]. 
Second, the number of outlier probes per sample was 
normalized by dividing it by the total number of CpG 
sites with data (i.e., not NAs) in the given individual.
DNA methylation by pyrosequencing
Genomic DNA from each sample was bisulfite converted 
using the EZ Gold DNA methylation kit (Zymo, Irvine, 
CA, USA), following manufacturer’s protocols. Primer 
sequences [42, 43] and reaction conditions for all pyrose-
quencing assays can be found in Additional file 1: Table 
S3. Within an assay, samples were randomized across 
pyrosequencing plates to reduce technical bias. For qual-
ity control, synthetic fully methylated and unmethyl-
ated samples (EpigenDx, Hopkinton, MA, USA) were 
included on each plate.
Repetitive elements–DNAm was averaged for four 
CpG sites in the LINE1 promoter and three CpG sites 
in Alu for assessment of repetitive element DNAm [42, 
43]. Samples with a single peak height <75 or SD > 10 % 
between assayed CpGs were repeated.
Chorionic villi candidate follow-up–Four CpG sites 
(cg1098862, cg02413938, cg17343385, cg24666096) were 
identified as DM in the 450k array comparison of AN to 
CON. Two of these sites (cg1098862, cg02413938) were 
followed-up by pyrosequencing in an extended group 
of samples since they were close to genes which may be 
of biological interest in NTDs. The other two sites were 
not followed-up by pyrosequencing since cg17343385 
overlaps a documented SNP (rs111359627, dbSNP141), 
which likely accounts for the observed difference in 
DNAm, and cg24666096 is >30 kb from the closest tran-
scription start site. DNAm by pyrosequencing was signif-
icantly correlated with array DNAm in the set of samples 
run on the 450k array [cg1098862, r =0.84 (p < 2.2e−16); 
cg02413938, r = 0.37 (p = 0.008)].
GO analysis
Gene ontology (GO) analysis was performed using 
ErmineJ [44]. For each tissue by NTD status compari-
son, genes associated with 450k CpG sites were ranked 
by magnitutde of unadjusted p values (smallest to largest) 
from the fitted linear models. Enrichment for GO classes 
was performed against the cleaned 450k array back-
ground using the following ErmineJ conditions: gene 
score resampling method, minimum gene set size of 
10, maximum gene set size of 200, using the best score 
for gene replicates, median class scoring, 200,000 itera-
tions, and full resampling. Gene ontology was conducted 
with the 748 persistent kidney spina bifida hits using the 
“quick list” option of the over-representation analysis 
(ORA) method in ErmineJ.
DMR analysis
Differentially methylated region (DMR) analysis was con-
ducted within a tissue on M values using the dmrFind 
function in the R charm package [45] with the following 
criteria to define a DMR: maximum gap between adjacent 
CpGs = 300 bps and ≥3 probes in identified DMRs. Fetal 
sex and gestational age were included as additive covari-
ates in the modeling of DMRs. Once DMRs were identi-
fied in the comparison of SB to CON and AN to CON, a 
q value correction for multiple comparisons was applied 
with 1000 iterations using the qval function in charm.
Publicly available data and analysis
Filtered and raw data for the 179 samples used in this 
publication were deposited in NCBI’s gene expression 
omnibus (GEO) [46] and are accessible through GEO 
Series accession number GSE69502 (http://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE69502).
Additional control fetal kidney (GEO CON) data 
were downloaded from GEO SuperSeries, GSE30654 
[47]. 450k data available for five fetal kidney samples of 
comparable gestational age (GSM868047, GSM868048, 
GSM868049, GSM868050, GSM868051) (Additional 
file 1: Table S5), were compared to our CON and SB kid-
ney samples. To validate the DM kidney SB CpGs, first 
those CpG sites demonstrating a post hoc association 
with technical confounding variables were filtered out, 
leaving 2644 of 3342 sites for further investigation. Then, 
our CON and SB samples were each compared to the 
GEO CON samples to assess replication of DM at an FDR 
<0.05. CpG sites that were DM between the two control 
groups were removed (n = 1536). Finally, only those CpG 
sites that were DM between our SB and the GEO CON 
samples were considered “persistent hits” (n = 748 of the 
2644 cleaned DM kidney SB CpGs).
Statistical software
All analyses were conducted in R statistical software [32]. 
p values for Tables 1, 2 were calculated by Mann–Whit-
ney test for continuous variables and Fisher’s exact test 
for categorical variables. For chorionic villi AN follow-up 
analyses, correlation of pyrosequencing and array data 
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was conducted using Spearman’s rank order correlation. 
A linear model with main effect NTD status and fetal sex 
and gestational age as additive covariates was fit to each 
follow-up CpG site. Correction for multiple comparisons 
was applied using Bonferroni correction. Graphics were 
created using the ggplot2 package [48].
Results
MTHFR genotyping
Two SNPs in MTHFR, 677C>T, and 1298A>C, were eval-
uated in our cases as (1) reduced MTHFR function has 
been reported for carriers of 677TT (~30 % function of 
controls) and 1298CC (~57  % function of controls) [10, 
11]; and (2) an association between the 677TT genotype 
and NTD status has been consistently reported (odds 
ratio of 1.8 for NTD infant carriers) [9]. In our small 
population, no difference in genotype frequency by 
NTD status was observed at the 1298 locus. A trend for 
increased T homozygotes at the 677 locus was present 
in both NTD groups compared to CON, although this 
did not reach statistical significance (Table 1). Given our 
small sample size, we did not evaluate additional genetic 
polymorphisms.
Differential methylation of biologically relevant candidate 
CpG sites
Specific disease-relevant loci may play a role in the 
development of NTDs through altered gene expres-
sion. These include genes for which mutations in mice 
lead to the development of NTDs, in addition to loci 
involved in one-carbon metabolism. As DNAm can 
either affect or reflect gene expression, we first assessed 
DNAm at 8393 candidate 450k CpG sites in 340 bio-
logically relevant genes (Additional file  1: Table S4). 
Within each tissue, a linear model was fit for every 
biologically relevant CpG site to test for differen-
tial methylation by NTD status, while controlling for 
fetal sex and gestational age. Differentially methylated 
(DM) CpG sites were those identified at a false dis-
covery rate (FDR) <0.05 and average group difference 
in DNAm (deltaβ) ≥0.05, when comparing SB to CON 
or AN to CON (see “Methods”). DM CpG sites were 
detected only in the kidney comparison of SB to CON 
(n  =  65,  0.8  % of biologically relevant candidate CpG 
sites), while comparisons in all other tissues did not 
meet the DM criteria (Additional file 1: Table S6). We 
conclude that aberrant DNAm of these biologically rel-
evant candidate loci is not a main feature of our NTD 
cases, with the exception of SB kidney.
Genome‑wide DNA methylation
Demand for one carbon units is high during times of 
rapid cell proliferation, development, and migration 
[12], such as in early embryo development. If OCM 
cycling is disrupted in NTD cases persisting in Brit-
ish Columbia, we expected that widespread changes in 
DNAm would be observed. We took several approaches 
to address this question. First, unsupervised hierar-
chical clustering of clean 450k CpG sites (n = 442,091 
CpGs, see “Methods”) gave an overall view of the rela-
tionship between study samples (Fig.  1). As expected, 
samples clustered primarily by tissue type, not the 
individual of origin. Tissues originating from the inner 
cell mass clustered closer together (i.e., brain and spi-
nal cord of ectodermal origin; muscle and kidney of 
mesodermal origin), while chorionic villi (of mixed 
trophectodermal/chorionic mesodermal origin) clus-
tered further away from the four somatic tissues. Nota-
bly, even within a tissue, there was no clear division of 
samples by NTD status, although we noted a cluster of 
eight SB and one AN in kidney, and of twelve SB and 
two CON in spinal cord (Fig. 1).
All cases of NTDs might not exhibit aberrant genome-
wide DNAm; their multifactorial inheritance suggests 
Table 2 Genome-wide DNA methylation by tissue
p values based on comparison of spina bifida to controls or anencephaly to controls. *p < 0.05 based on 1000 permutations of Mann–Whitney test, **p < 0.01 based 
on 1000 permutations of Mann–Whitney test. SD standard deviation
Chorionic villi Kidney Spinal cord Brain Muscle
Median array average ± SD (n) Control 0.432 ± 0.006 (16) 0.471 ± 0.004 (16) 0.486 ± 0.002 (9) 0.486 ± 0.004 (11) 0.484 ± 0.004 (13)
Spina bifida 0.427 ± 0.007 (22)** 0.470 ± 0.003 (20) 0.481 ± 0.004 (17)* 0.482 ± 0.004 (9) 0.484 ± 0.003 (10)
Anencephaly 0.425 ±0.007 (14)* 0.468 ± 0.003 (8) 0.485 ± 0.003 (6) – 0.484 ±0.003 (8)
Median % LINE1 DNAm ± SD (n) Control 55.8 ± 3.8 (16) 79.2 ± 1.5 (16) 79.9 ± 1.5 (9) 81.5 ± 2.0 (11) 80.3 ± 1.4 (13)
Spina bifida 56.7 ± 3.0 (22) 78.3 ± 2.1 (20) 80.9 ±1.7 (17) 83.2 ± 1.4 (9) 80.9 ± 1.6 (10)
Anencephaly 55.0 ± 2.9 (14) 78.5 ± 1.4 (8) 79.7 ± 1.7 (6) – 80.5 ± 1.4 (8)
Median % Alu DNAm ± SD (n) Control 22.6 ±1.1 (16) 24.7 ± 1.2 (16) 25.0 ± 0.9 (9) 25.6 ± 1.6 (11) 24.2 ±1.0 (13)
Spina bifida 22.3 ± 1.1 (22) 24.8 ± 1.5 (20) 26.1 ± 1.6 (17) 25.4 ± 1.2 (9) 25.0 ± 2.2 (10)
Anencephaly 22.8 ± 1.3 (14) 24.1 ± 2.1 (8) 25.4 ± 0.9 (6) – 24.5 ± 0.6 (8)
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that the etiology of this disease is heterogeneous. Thus 
second, we calculated both (1) the 450k array average 
DNAm per sample (Table  2; Additional file  2: Fig. S1) 
and (2) the percentage of outlying CpG sites per sample 
(Additional file  2: Fig. S2). Using 1000 permutations of 
the Mann–Whitney test, a slight reduction in array aver-
age DNAm was noted in chorionic villi for SB vs. CON 
(−0.005, p  <  0.01) and AN vs. CON (−0.007, p  <  0.05; 
Table 2). Comparing between NTD status groups, there 
was no difference in the number of outlier samples based 
on either of these measures.
Finally, a different assay was used to measure global 
DNAm in all samples—pyrosequencing of the repetitive 
elements LINE1 and Alu [42, 43]. LINE1 and Alu repeti-
tive elements are scattered throughout the genome and 
their DNAm has been shown to be sensitive to environ-
mental changes [49–52]. These repetitive elements are 
not densely covered by the 450k array and thus, they 
were used to assess DNAm at other genomic regions. 
There was no statistical difference in repetitive element 
DNAm by NTD status in any of the studied tissues 
(Table 2).
Differential methylation of CpG sites array‑wide
We next explored whether specific CpG sites with 
unknown relationship to NTDs exhibited altered DNAm 
by testing for differential methylation (DM) at each 450k 
array target. Within a tissue, a linear model was fit per 
CpG site to test for DM by NTD status while controlling 
for fetal sex and gestational age. The distribution of unad-
justed p values from the comparisons of SB and AN to 
CON cases gives a broad view of the pattern of DM by 
NTD status (Fig. 2). A uniform distribution of p values, 
for example, in the AN spinal cord comparison, indicates 
equal likelihood of DM and non-DM. Left-peaking dis-
tributions (e.g., SB kidney or spinal cord comparisons), 
indicate a greater likelihood of DM than non-DM, sug-
gesting that a subset of loci show altered DNAm in these 
tissues. These differences, however, must pass correction 
for multiple comparisons to be considered significant 
CpGs of interest.
An FDR correction was applied to the p values obtained 
from the fitted linear models; additionally, for every 
CpG site, the average CON DNAm was subtracted from 
the average SB or AN DNAm (deltaβ). Plotting deltaβ 
Fig. 1 Sample clustering based on array‑wide DNA methylation. Unsupervised hierarchical clustering of 442,091 CpG sites clustered samples 
primarily by tissue type. Within a tissue, samples did not cluster by NTD status. We did note however, a cluster of eight spina bifida and one anen‑
cephaly in kidney and a cluster of 12 spina bifida and two controls in spinal cord
Fig. 2 Tissue distribution of unadjusted p values from linear mod‑
eling of differential methylation in NTDs. Distribution of p values 
from the comparison of DNA methylation for spina bifida to control 
samples at each of 442,091 CpG sites (left) and for anencephaly to 
controls samples at each of 442,091 CpG sites (right), including fetal 
gestational age and sex as additive covariates. Flat distributions 
indicate equal likelihood of significant and non‑significant tests, while 
left-peaking distributions indicate greater likelihood of significant tests
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against FDR for each CpG site demonstrated remarkably 
few extreme differences in most of the tissue compari-
sons, except for the comparison of SB kidneys to CON 
kidneys (Fig. 3; Additional file 2: Fig. S3). The deltaβ on 
the x-axis of these volcano plots (Fig. 3) suggests that the 
array-wide difference in average DNAm noted in chori-
onic villi in the previous section (Table 2) is representa-
tive of small changes in DNAm across many CpGs. At a 
statistical threshold of FDR <0.05, 4148 CpG sites were 
DM in the kidney comparison of SB to CON, one CpG 
site was DM in the spinal cord comparison of SB to CON, 
and five CpG sites were DM in the chorionic villi com-
parison of AN to CON (Additional file 1: Table S7). The 
application of a second filter, a minimum deltaβ of 0.05 to 
enhance for biologically meaningful differences between 
groups, reduced the number of DM CpG sites to 3342 in 
the kidney comparison of SB to CON and four (Fig. 4) in 
the chorionic villi comparison of AN to CON (discussed 
in next section).
Four approaches were taken to reduce the risk that 
findings from the above DM analysis were not limited 
due to threshold cutoffs, sample size, or small differ-
ences in DNAm. First, the top 1000 ranking DM CpG 
sites were overlapped (1) within a tissue by NTD status 
(Additional file  2: Fig. S4), and (2) within an NTD sta-
tus across all tissues (Additional file  2: Fig. S5). There 
was little overlap of top ranking DM CpG sites in either 
comparison.
Second, for each tissue and NTD status comparison, 
a gene ontology (GO) analysis was conducted with all 
unadjusted p values to rank genes associated with CpG 
sites on the array. The only GO classes significant at an 
FDR <0.10 were “nuclear-transcribe mRNA catabolic 
process, nonsense-mediated decay” (GO:0000184, 111 
genes) in the chorionic villi SB to CON comparison and 
“production of molecular mediator involved in inflam-
matory response” (GO:0002532, 13 genes) in the spinal 
cord AN to CON comparison.
Fig. 3 Spina bifida array‑wide volcano plots. Volcano plots comparing the magnitude of difference in DNAm (adjusted delta beta) to statistical 
significance (−log10(adjusted P.Value)) for each CpG site (n = 442,091) in spina bifida vs. control samples
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Third, we assessed DM regions (DMRs) rather than 
DM CpG sites to integrate information from neighbor-
ing CpG sites and reduce the number of comparisons in 
statistical tests. DMRs were identified in each of the tis-
sue by NTD status comparisons, but after correction for 
multiple comparisons, none were significant.
Finally, a subgroup analysis was performed to confirm 
that unequal group gestational ages (Table  1) did not 
obscure differential DNAm between SB and CON com-
parisons in chorionic villi, brain, spinal cord, or muscle. 
With the exception of four sites in chorionic villi, no signif-
icant differences in DNAm were noted between the gesta-
tional age-matched AN and CON groups. This allowed the 
AN and CON cases to be combined into a “non-SB” group, 
from which 19 samples (19–24  weeks) were selected for 
a gestational age-matched comparison to SB (Additional 
file 2: Fig. S6). DM between the non-SB and SB groups was 
tested by fitting a linear model within each tissue for NTD 
status with gestational age and sex as additive covariates. 
No CpG sites were DM at FDR <0.05 in this supplemental 
gestational age-matched comparison, thus differences in 
gestational age between SB and CON groups do not likely 
contribute to the lack of statistical difference observed in 
most of the SB tissues. These supplemental analyses, in 
addition to the array-wide volcano plots (Fig. 3; Additional 
file 2: Fig. S3), suggest that aberrant genome-wide DNAm 
is present in SB kidneys, but may not be a major feature of 
the other NTD tissues assessed in this study.
Follow‑up of differentially methylated CpG sites in kidney 
and chorionic villi
To confirm the unique findings in kidney SB, we com-
pared our SB cases and CON to 450k data from five inde-
pendent control second trimester fetal kidney samples 
downloaded from GEO (GEO CON; Additional file  1: 
Table S5). Of the 4148 CpG sites identified as DM in the 
previous section at FDR <0.05, 2644 (64  %) remained 
DM at FDR <0.05 when comparing our SB kidneys to the 
GEO CON kidneys. A subset of 748 higher confidence 
CpG sites, termed persistent hits, was selected for use 
in follow-up analyses in SB kidneys. Persistent hits were 
refined using four filters: (1) CpG sites identified as DM 
at FDR <0.05 and deltaβ  ≥0.05 in the previous section 
when comparing our SB to CON kidneys (3342 of 4148); 
(2) CpG sites where a post hoc test revealed no associa-
tion with study covariates—gestational age, sex, plate, 
chip, or row (2644 of 3342); (3) CpG sites where the two 
control groups exhibited no DM at FDR <0.05 (1536 
of 2644); and (4) CpG sites with DM at FDR <0.05 and 
deltaβ ≥0.05 between our SB and the GEO CON samples 
(748 of 1536). Persistent hits were under-represented in 
high-density CpG islands (p < 2.2e–16) and enriched in 
non-islands (p  <  2.2e–16) and enhancers (p  <  2.2e-16) 
(Fig.  5a), and were not enriched for any GO terms. As 
expected, supervised clustering of our kidney samples 
using only these 748 persistent hits almost entirely sepa-
rated the SB from CON cases, though interestingly, two 
distinct clusters emerged within the SB cases (Fig.  5b). 
These two SB clusters, however, did not separate by sex, 
gestational age, location of the defect, or MTHFR geno-
type. The persistent hits were not followed-up as they 
appear to be secondary changes, and are not likely linked 
to our etiology of NTD hypothesis.
Four sites (cg1098862, cg02413938, cg17343385, 
cg24666096) were identified as DM in the AN vs. CON 
comparison in chorionic villi (Fig.  4). Pyrosequenc-
ing assays (Additional file 1: Table S3) were designed to 
follow up two of these CpG sites using this independ-
ent technique in the chorionic villus samples run on the 
450k array (n =  16 CON, 22 SB, 14 AN) in addition to 
an extended set of chorionic villi samples (n =  9 CON, 
9 SB, 11 AN; Additional file  1: Table S2). Follow-up of 
cg17343385 was excluded as a post hoc search of UCSC 
genome browser indicated that this probe targeted a SNP 
not excluded in the filtering steps of data processing. In 
the case of cg24666096, follow-up was not conducted as 
Fig. 4 Differentially methylated CpG sites in the chorionic villi 
comparison of anencephaly cases to controls. Four CpG sites were 
identified as significantly differentially methylated at an FDR <0.05 
and deltaβ ≥0.05. Each plot is labeled with the 450k CpG site identi‑
fier, the gene which it is closest to and average difference in DNAm 
between anencephaly and controls (deltaβ). Box edges are plotted 
at the 25th and 75th percentiles (the inter‑quartile range (IQR)) and 
whiskers are plotted to the last sample within ± 1.5*IQR
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no nearby functional genomic elements were annotated 
in UCSC genome browser (i.e., TF binding sites, TSS, 
or ENCODE enhancers) making it currently difficult to 
interpret the biological relevance of altered DNAm at 
such a location. The difference in DNAm at cg10988628, 
146 bps upstream of PARP1, was validated by pyrose-
quencing in the samples run on the array (p = 0.000006, 
Additional file 2: Fig. S7) and replicated in the extended 
samples (p  =  0.02). The difference in DNAm observed 
at cg02413938, 21 bps upstream of ESPNL, was also 
validated by pyrosequencing in the samples run on the 
array (p  =  0.05), although it was not replicated in the 
extended samples (Additional file 2: Fig. S8A). DNAm at 
this CpG site may be linked to a SNP 6 bps downstream 
(rs6431579), and it is therefore possible that cg02413938 
was picked up in the 450k DM analysis due to unequal 
genotype distribution between NTD status groups (Addi-
tional file 2: Fig S8B).
Discussion
Increased methyl group availability is one of the proposed 
mechanisms for how folic acid (FA) fortification contrib-
uted to the worldwide reduction of NTDs. We profiled 
DNA methylation (DNAm) in five fetal tissues ascer-
tained from cases of NTDs in British Columbia, a folate 
replete population, to test whether abnormal DNAm 
was a feature of NTDs that develop despite FA fortifica-
tion. Barring distinctive DNAm in the kidneys of spina 
bifida (SB) cases, neither aberrant CpG site-specific nor 
genome-wide DNAm were characteristic of the tissues 
in this cohort. Aside from our main findings, there were 
remarkably few changes in DNAm in anencephalic (AN) 
fetuses, which suggests that normal fetal neural function 
may not be required for placental and fetal development 
through the second trimester.
Though tissues directly involved in the neural tube 
defect—spinal cord and brain—had largely normal 
DNAm in NTDs, a tissue peripheral to the defect—kid-
ney—was the one dramatic exception to this pattern, 
with 4148 CpG sites (FDR < 0.05) identified as differen-
tially methylated (DM) sites in spina bifida (SB). This dis-
tinct pattern may be reflective of cell type heterogeneity 
in kidney, consistency of tissue sampling and/or true dif-
ferences in DNAm, and warranted further investigation. 
When compared to a publically available control kidney 
group, 64 % of the kidney SB vs. CON sites remained dif-
ferentially methylated, increasing confidence in this dis-
tinctive DNAm profile. However, this was not an ideal 
validation, as an independent SB group was not also 
available.
About 50  % of people living with SB exhibit abnor-
mal urodynamics, which in many cases leads to severe 
renal complications [53]. However, only about 8–9 % of 
SB cases present with a congenital renal abnormality at 
birth, including for example renal agenesis, horseshoe 
kidney, or ureteral duplication [54, 55]. All of the 20 SB 
Fig. 5 Identification and investigation of persistent hits in spina bifida kidneys. a By comparing our spina bifida (SB) and control (CON) samples to 
an independent control group (n = 5, GEO CON), 748 of the differentially methylated kidney spina bifida CpG sites were identified as persistent hits. 
Persistent hits were enriched for CpG sites located in enhancers and outside of CpG islands. b Hierarchical clustering of our spina bifida and control 
samples based solely on persistent hits almost completely separated the spina bifida from control cases, and two groups of SB cases emerged
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cases in this study were found to have histologically nor-
mal kidneys on autopsy, and thus grossly abnormal renal 
morphology does not likely account for the differential 
methylation we observed. Caudal neural tube closure 
should occur at around day 28 of gestation and the ure-
teric buds, which induce differentiation of the kidneys, 
develop at about day 30–32 [54]. Thus, an environmen-
tal disruption during this window of pregnancy leading 
to the development of an NTD might also be related to 
the abnormal kidney DNAm observed here [53]. Alterna-
tively, this abnormal pattern of DNAm might be related 
to dysregulated innervation from the spinal cord during 
renal development. Sympathetic renal innervation origi-
nates from the T10 to L1 regions of the spinal cord [56] 
and is posited to play a role in the cellular and biochemi-
cal development of this organ during gestation [57]. Of 
our 20 SB kidneys, the highest intact level of the spinal 
cord was known for 15 cases: above T10—2 cases, T10-
L1 region—3 cases, L2-L3—7 cases, L4-L5—2 cases, and 
S1—1 case. Given the distribution of location of defects 
in our cases and the lack of biological pathway enrich-
ment in the persistent DM kidney CpGs, we suggest that 
the abnormal kidney DNAm does not likely give rise to 
the NTD.
Placental chorionic villi was a tissue we predicted might 
be more likely to exhibit changes in DNAm in NTDs. 
Placental DNAm may be particularly sensitive to the in 
utero environment [58], since this organ is designed to 
respond to fetal, as well as maternal, signals. The placenta 
is also responsible for nutrient acquisition from maternal 
circulation during gestation. Decreased placental weight 
and increased placental immaturity has been reported in 
anencephalic pregnancies at term [59, 60]. There was a 
weak trend for differential methylation in several of our 
chorionic villi analyses, though overall, we noted rela-
tively little significant change in NTDs. One of the sig-
nificant DM sites we identified (cg10988628) may be of 
interest in NTDs, since it is located 146 bps upstream of 
poly (ADP-Ribose) Polymerase 1 (PARP1). This gene is 
known to regulate trophoblast differentiation [61], and 
is involved in ADP-ribosylation of histones [62], and its 
loss of function is associated with invasive and meta-
static properties in cancer [63]. However, the changes we 
noted were subtle in AN-associated placentas, and would 
require a larger sample size to characterize.
To our knowledge, there has been one other study of 
genome-wide DNAm in NTD placenta, which used the 
450k array to compare DNAm of eight normal (40 weeks 
gestational age) to eight SB (27–40 weeks gestational age) 
placentas [64]. The authors identified 3839 DM sites at a 
p value = 0.01 and fold change = 0.2. A stricter thresh-
old for DM was used in the current study, FDR <0.05 and 
deltaβ  ≥0.05, as is recommended for EWAS to reduce 
false positive results [65]. Using these same criteria, we 
previously observed dramatic differences in the DNAm 
of chorionic villi in other, less severe conditions such as 
preeclampsia (30,248 CpG sites), and trisomy confined to 
the placenta (24,621 CpG sites) [66, 67], versus only four 
sites identified here in AN and none in SB. The difference 
in results between Zhang et al. [64] and the current study 
is likely related to use of different thresholds for signifi-
cance, correction for multiple comparisons, smaller sam-
ple size, and non-overlapping gestational age of cases and 
controls.
Our ability to detect significant differences at indi-
vidual CpGs in any of the tissues studied here may have 
been limited by (1) large variation in DNAm within a 
group, (2) pathological heterogeneity of the CON group, 
(3) between group differences in gestation age, (4) small 
average group differences in DNAm, and/or (5) sample 
size given 1–4. We also did not have access to impor-
tant clinical information such as use of periconceptional 
folic acid or maternal ethnicity, though ethnic differences 
between cases and controls are expected to lead to false 
positives and are unlikely to cause false negatives. Fur-
thermore, since the same individuals contributed mul-
tiple tissues to the study, if mismatched ethnicity was 
driving these differences in DNAm, we would have seen 
overlap of top-ranking sites across tissues (Additional 
file 2: Figure S5). As evidenced by the findings in SB kid-
neys, our study, despite these limitations was sufficient 
in size to indicate that large and widespread differences 
in DNAm are not a consistent feature of nervous or pla-
cental tissues from NTDs in British Columbia, Canada. 
However, an independent study in a larger cohort, cover-
ing CpG sites beyond those targeted by the 450k micro-
array, will be needed to definitively determine if small 
alterations in DNAm at specific sites are yet another 
contributing factor in the multifactorial development of 
NTDs.
Conclusions
Most studies of pregnancy are limited to sampling pla-
centa, cord blood, amniotic fluid, or extraembryonic 
membranes; tissues which may have limited applicabil-
ity to the disease in question. In this study of neural tube 
defect (NTD) cases and controls, the Illumina 450k plat-
form was used to profile DNA methylation (DNAm) at 
more than 450,000 biologically relevant CpG sites across 
the genome in placenta (chorionic villi), kidney, spinal 
cord, brain, and muscle tissue obtained from 56 fetuses. 
The use of this unique set of tissues increases biological 
relevance, and the data provide a novel resource for those 
studying DNAm during fetal development. We found 
aberrant array-wide DNAm in the kidneys of spina bifida 
cases, but this was not apparent in other spina bifida 
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or anencephaly-associated tissues. Examination of the 
DNAm profile of organs with spinal innervation origi-
nating below that of the kidney, such as the bladder, may 
provide further evidence for or against our hypothesis for 
the observed differential methylation in spina bifida kid-
neys. The findings of this study were inconsistent with a 
generalized phenomenon of altered DNAm in NTDs that 
persist in folate replete populations, though we cannot 
exclude the DNAm hypothesis in other circumstances 
(i.e., nutritional environment, demographics, tissues) or 
regions of the genome not assessed by this study. Other 
mechanisms, such as changes in non-DNAm regula-
tion of gene expression, altered cell cycle length, or defi-
ciency of vitamins involved in one-carbon metabolism 
are areas of investigation that may provide further clues 





450k array: Illumina Infinium HumanMethylation450 BeadChip; AN: anen‑
cephaly; chr: chromosome; CON: control; deltaβ/delta beta: difference in 
average DNA methylation; DM: differentially methylated or differential meth‑
ylation; DMR: differentially methylated region; DNAm: DNA methylation; FA: 
folic acid; FDR: false discovery rate; GEO: gene expression omnibus; GEO CON: 
control kidney samples downloaded from GEO; GO: gene ontology; MTHFR: 
methylenetetrahydrofolate reductase; ns: not significant; NTD: neural tube 
defect; OCM: one carbon metabolism; QC: quality control; SB: spina bifida; SD: 
standard deviation; wks: weeks; yrs: years.
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